New developments in systemic therapy for hepatocellular carcinoma

摘要: Hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancers. ΗCC is the fifth most common malignancy and third cause of cancer death globally (more than 500.000 cases yearly) with deaths occurring within one year diagnosis.1,2 In 90-95% οf cases, HCC developed in cirrhotic liver. Liver transplantation (from cadaveric or living donors), surgical resection, percutaneous ethanol injection, transcatheter arterial chemoembolizatin (TACE) radio-frequency (RF) thermal ablation microwaves achieve a relatively high response rate only carefully selected candidates small (diameter < 5 cm) tumors. Hepatic reserve often dictates the therapeutic options. Systemic therapy appropriate for patients advanced unresectable disease who are unsuitable for locoregional carry dismal prognosis. Nevertheless, up until now, there have been multitudes of negative systemic trials advanced HCC.3 So, 60-75% HCC Europe the USA, no short palliative approaches was given to patients.4,5,6,7